Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist

ACS Medicinal Chemistry Letters

Volumn 7, Issue 12, 2016, Pages 1134-1138

  Agarwal, Sameer ^a   Sasane, Santosh ^a   Deshmukh, Prashant ^a   Rami, Bhadresh ^a   Bandyopadhyay, Debdutta ^a   Giri, Poonam ^a   Giri, Suresh ^a   Jain, Mukul ^a   Desai, Ranjit C ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

fatty acids; FFAR1; GPR40; GPR40 agonist; insulin secretion; type 2 diabetes

Indexed keywords

3 (4 ARYLOXYARYL)PROPANOIC ACID DERIVATIVE; 3 [4 [[3 [[ISOPROPYL (THIOPHEN 3 YLMETHYL)AMINO]BENZYL]OXY]PHENYL]HEX 4 YNOIC ACID CALCIUM SALT; ARYLPROPIONIC ACID DERIVATIVE; CYTOCHROME P450; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; MOLECULAR SCAFFOLD; ORAL ANTIDIABETIC AGENT; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CACO-2 CELL LINE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; EC50; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; LIPOPHILICITY; LIVER MICROSOME; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METABOLIC STABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION;

EID: 85002522336     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00331     Document Type: Article

References (27)

1. IBD Diabetes Atlas, 6th ed.; International Diabetes Federation: Brussells, Belgium, 2013; http://www.diabetesatlas.org.
2. Defronzo, R. A. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus Diabetes 2009, 58, 773-795 10.2337/db09-9028
3. Kles, K. A.; Vinik, A. I. Curr. Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component Curr. Diabetes Rev. 2006, 2, 131-145 10.2174/157339906776818569
4. Ashiya, M.; Smith, R. E. T. Non-insulin therapies for type 2 diabetes Nat. Rev. Drug Discovery 2007, 6, 777-778 10.1038/nrd2420
5. Ahrén, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes Nat. Rev. Drug Discovery 2009, 8, 369 10.1038/nrd2782
6. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40 Nature 2003, 422, 173-176 10.1038/nature01478
7. Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; Petrov, A.; Zhou, C.; Lin, S.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T. E.; Einstein, M.; Kumar, S.; Berger, J. P.; Mills, S. G.; Thornberry, N. A.; Yang, L.; Howard, A. D. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice Diabetes 2008, 57, 2211-2219 10.2337/db08-0130
8. Rayasam, G. V.; Tulasi, V. K.; Davis, J. A.; Bansal, V. S. Fatty acid receptors as new therapeutic targets for diabetes Expert Opin. Ther. Targets 2007, 11, 661-671 10.1517/14728222.11.5.661
9. Defossa, E.; Wagner, M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 2014, 24, 2991-3000 10.1016/j.bmcl.2014.05.019
10. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist ACS Med. Chem. Lett. 2010, 1 ( 6 ) 290-294 10.1021/ml1000855
11. Christiansen, E.; Hansen, S. V.; Urban, C.; Hudson, B. D.; Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker, C. J.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Milligan, G.; Cawthorne, M. A.; Ulven, T. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes ACS Med. Chem. Lett. 2013, 4, 441-445 10.1021/ml4000673
12. Houze, J. B.; Zhu, L.; Sun, Y.; Akerman, M.; Qiu, W.; Zhang, A. J.; Sharma, R.; Schmitt, M.; Wang, Y.; Liu, J.; Liu, J.; Medina, J. C.; Reagan, J. D.; Luo, J.; Tonn, G.; Zhang, J.; Lu, J. Y. L.; Chen, M.; Lopez, E.; Nguyen, K.; Yang, L.; Tang, L.; Tian, H.; Shuttleworth, S. J.; Lin, D. C.-H. AMG 837: A potent, orally bioavailable GPR40 agonist Bioorg. Med. Chem. Lett. 2012, 22, 1267-1270 10.1016/j.bmcl.2011.10.118
13. Garrido, D. M.; Corbett, D. F.; Dwornik, K. A.; Goetz, A. S.; Littleton, T. R.; McKeown, S. C.; Mills, W. Y.; Smalley, T. L.; Briscoe, C. P.; Peat, A. J. Synthesis and activity of small molecule GPR40 agonists Bioorg. Med. Chem. Lett. 2006, 16, 1840-1845 10.1016/j.bmcl.2006.01.007
14. Zhou, C.; Tang, C.; Chang, E.; Ge, M.; Lin, S.; Cline, E.; Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; Petrov, A.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T. E.; Einstein, M.; Kumar, S.; Berger, J.; Howard, A. D.; Thornberry, N.; Mills, S. G.; Yang, L. Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists Bioorg. Med. Chem. Lett. 2007, 20, 1298-1301 10.1016/j.bmcl.2009.10.052
15. Hansen, S. V. F.; Christiansen, E.; Urban, C.; Hudson, B. D.; Stocker, C. J.; Due-Hansen, M. E.; Wargent, E. T.; Shimpukade, B.; Almeida, R.; Ejsing, C. S.; Cawthorne, M. A.; Kassack, M. U.; Milligan, G.; Ulven, T. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy J. Med. Chem. 2016, 59, 2841-2846 10.1021/acs.jmedchem.5b01962
16. Takano, R.; Yoshida, M.; Inoue, M.; Honda, T.; Nakashima, R.; Matsumoto, K.; Yano, T.; Ogata, T.; Watanabe, N.; Hirouchi, M.; Yoneyama, T.; Ito, S.; Toda, N. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist ACS Med. Chem. Lett. 2015, 6 ( 3 ) 266-270 10.1021/ml500391n
17. Lin, D. C.; Zhang, J.; Zhuang, R.; Li, F.; Nguyen, K.; Chen, M.; Tran, T.; Lopez, E.; Lu, J. Y. L.; Li, X. N.; Tang, L.; Tonn, G. R.; Swaminath, G.; Reagan, J. D.; Chen, J.-L.; Tian, H.; Lin, Y.-J.; Houze, J. B.; Luo, J. AMG 837: A novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents PLoS One 2011, 6, e27270 10.1371/journal.pone.0027270
18. Naik, H.; Vakilynejad, M.; Wu, J.; Viswanathan, P.; Dote, N.; Higuchi, T.; Leifke, E. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers J. Clin. Pharmacol. 2012, 52, 1007-1016 10.1177/0091270011409230
19. Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebocontrolled, phase III trial. Diabetes Diabetes, Obes. Metab. 2015, 17, 675-681 10.1111/dom.12467
20. Agarwal, S.; Patil, A.; Aware, U.; Deshmukh, P.; Darji, B.; Sasane, S.; Sairam, K. V. V. M; Priyadarsiny, P.; Giri, P.; Patel, H.; Giri, S.; Jain, M.; Desai, R. C. Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist ACS Med. Chem. Lett. 2016, 7 ( 1 ) 51-55 10.1021/acsmedchemlett.5b00323
21. Liu, J.; Wang, Y.; Ma, Z.; Schmitt, M.; Zhu, L.; Brown, S. P.; Dransfield, P. J.; Sun, Y.; Sharma, R.; Guo, Q.; Zhuang, R.; Zhang, J.; Luo, J.; Tonn, G. R.; Wong, S.; Swaminath, G.; Medina, J. C.; Lin, D. C.-H.; Houze, J. B. Optimization of GPR40 Agonists for Type 2 Diabetes ACS Med. Chem. Lett. 2014, 5, 517-521 10.1021/ml400501x
22. Waring, M. J.; Arrowsmith, J.; Leach, A. R.; Leeson, P. D.; Mandrell, S.; Owen, R. M.; Pairaudeau, G.; Pennie, W. D.; Pickett, S. D.; Wang, J.; Wallace, O.; Weir, A. An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat. Rev. Drug Discovery 2015, 14, 475-486 10.1038/nrd4609
23. Kumar, G. N.; Surapaneni, S. Role of drug metabolism in drug discovery and development Med. Res. Rev. 2001, 21 ( 5 ) 397 10.1002/med.1016
24. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures J. Org. Chem. 1996, 61 ( 11 ) 3849-3862 10.1021/jo960057x
25. Walker, S. D.; Borths, C. J.; DiVirgilio, E.; Huang, L.; Liu, P.; Morrison, H.; Sugi, K.; Tanaka, M.; Woo, J. C. S.; Faul, M. M. Development of a Scalable Synthesis of a GPR40 Receptor Agonist Org. Process Res. Dev. 2011, 15, 570-580 10.1021/op1003055
26. Shafrir, E. Animal models of non insulin dependent diabetes Diabetes/Metab. Rev. 1992, 8, 179-208 10.1002/dmr.5610080302
27. Ito, R.; Tsujihata, Y.; Suzuki, M.; Miyawaki, K.; Matsuda, K.; Takeuchi, K. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas J. Pharmacol. Exp. Ther. 2016, 357 ( 1 ) 217-27 10.1124/jpet.115.230730